Tetra Bio-Pharma Inc (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1) said on Friday that the biotechnology company has initiated other research projects with Targeted Pharmaceuticals, through its research agreement with the George Mason University NCBID, to investigate the potential benefits of its lead drug candidate ARDS-003 in neuroinflammation and other antiviral applications.
In a statement, Tetra Bio-Pharma CEO Dr Guy Chamberland said: "We have initiated this new research agreement to further understand the potential therapeutic benefits of ARDS-003 in treating inflammatory conditions of the brain as well as learning more about the potential use of the drug candidate in other antiviral applications.”
“The partnership with Targeted provides expertise into these areas of drug development that are critical for expanding the potential Return on Investment (ROI) of our lead drug candidate ARDS-003," he added.
READ: Tetra Bio-Pharma says its contract manufacturing facility receives notice of compliance following an audit by Health Canada
The Ottawa, Canada-based pioneer in immunomodulator drug discovery and development, cited figures from The Business Research Company which estimate the global central nervous system drugs market growing at a CAGR of 6% to $163.05 billion in 2025 from $125.28 billion in 2020.
Outside of ARDS-003, the company is advancing a full pipeline of other drug candidates - CAUMZ is targeted towards uncontrolled pain and cancer; PPP-003 is a possible inflammatory eye treatment; HCC-011 is for chemotherapy-induced nausea; and QIXLEEF is being developed as a strong painkiller.
Contact the author Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive